Independent Data Lab’s Post

𝐖𝐞𝐥𝐜𝐨𝐦𝐞 𝐭𝐨 𝐭𝐡𝐞 𝐂𝐥𝐮𝐬𝐭𝐞𝐫 | 𝐊𝐲𝐨𝐨𝐁𝐞 𝐓𝐞𝐜𝐡 𝐆𝐦𝐛𝐇 🎉 The BioPharma Cluster South Germany welcomes its new member KyooBe Tech GmbH. With its interdisciplinary team of biotechnologists, IT experts, engineers and process engineers, the company addresses the technical challenges of manufacturing processes in the pharmaceutical industry. Founded in 2019, the foundation of KyooBe Tech has a strong affiliation with Bausch+Ströbel SE + Co. KG, a globally trusted partner for supply in Fill & Finish, with which the company shares a close strategic partnership. KyooBe Tech focuses on developing and commercialising of innovative production technologies for biopharmaceuticals, combining state-of-the-art robotics, automation and biotechnological expertise to create sustainable and integrated process solutions. The key areas of activity involve pathogen inactivation and the automated production of personalized cell and gene therapies. We are looking forward to the new partnership and are happy that the leading European ecosystem in the research-based manufacturing of biopharmaceuticals is now getting even stronger with KyooBe Tech as a new member of the BioPharma Cluster South Germany. 🍀 #Biopharmaceuticals #NewModalities #ProcessOptimization #FillFinish #Robotics #BioPharma #Biotech #Vaccine #BioPharmaNews #CGT

JPM24, Day 3 Overview: Gene editors talk business development; Roivant CEO has money to spend After selling off Telavant to Roche for $7.1 billion last year, Roivant is flush with cash, with no need to raise funds. The CEO explained how they plan to spend their capital, which sits at $7 billion, a significant strong position. The company utilised the meeting of investors, not to raise money, but to meet prospective partners and discuss new opportunity with their new position. Intellia Therapeutics assured the FDA that its gene edits are safe and effective for patients. The company spoke about the launching of their preclinical reproductive toxicity study that has reported very successful. The company has also benefited from a regenerative medicine advanced therapy, providing them better communication with the FDA. CRISPR Therapeutics are hot off the heels of their sickle cell gene therapy Casgevy. However, CEO Sam Kulkarni, Ph.D., said there is still room for business development in the gene editing biotech’s future. Editas Medicine’s Chief Financial Officer Erick Lucera spoke on the company after Vertex Pharmaceuticals entered a deal worth $100 million to the rights of Editas’ Cas9 gene-editing tech last month. He said in terms of potential deals Editas can either gain access to technology that other companies have via licensing or provide non-dilutive capital to continue to fund Editas’ product development. Read more about Day 3: #jpm2024 #roivant #genetherapy #therapeutics

🌟 Elevate Your Bioanalytical Strategy at Immunotherapies Xchange 2024! 🌟 Join us for an insightful roundtable discussion led by industry experts Matt Revitt and Wendy VanScyoc from MESO SCALE DIAGNOSTICS, LLC.. 🧪 They will tackle "Efficiency in Creating Methods for Bioanalytical Endpoints in ADA, PK, and PD Assays" – an essential session for professionals focused on improving bioanalytical testing workflows. 💡 With over 20 years of experience, Matt Revitt brings a wealth of knowledge from his role as Managing Director of Strategic Services at Meso Scale. His expertise spans developing efficient bioanalytical testing strategies and managing global partnerships with leading pharma and biotech companies. 🔬 📅 Date: Tuesday, October 29, 2024 📍 Location: College Park Marriott, Maryland 💼 Key discussion points: 🛡️ Mitigating critical reagent risks 🧬 Advancing bioanalytical methods for cell and gene therapies ⏱️ Enhancing efficiency in ADA, PK, and PD assay development This is your opportunity to engage with top experts, learn the latest strategies, and expand your network. 🌐 👉 View the full agenda and register today: https://lnkd.in/egBpKRqc 💊Only available for Senior Scientists and above, from Bio and Pharma companies, with a drug pipeline. #Immunotherapies #BioanalyticalAssays #Pharma #Biotech #ClinicalDevelopment #ADA #PK #PD #AssayDevelopment #Efficiency #CellTherapy #GeneTherapy #ReagentRisk #Biomarkers #Innovation #Networking #MesoScale #ExpertDiscussion #DrugDevelopment #Biopharma #hubXchange #Xchanges #Roundtable #FreePass #RegisterNow #ComplimentaryPass

Strong Innovation Fuels M&A Activity... Just came across a great piece by PwC highlighting a surge in biopharma deal-making across the industry. Innovation in areas like antibody-drug conjugates and cell and gene therapies is a big driver, with big pharma players seemingly on the hunt for promising early-stage biotech assets (though overall biotech deal values are down slightly year-over-year). Stable economic conditions are fueling investor confidence, making M&A a hot option for growth. This trend is expected to stay strong through 2024 and beyond!

Networking Opportunities! Did you know that Moderna, Capricor Therapeutics, Inc., Novo Nordisk, AstraZeneca, Takeda and more are amongst the 80+ leaders uniting at the 3rd Non-Viral RNA Delivery Systems Summit? Why is this your premium opportunity for non-viral delivery connections? 📢 Speed Networking: Connect with industry leaders & innovators in lightning-fast rounds 📢 Networking Breaks: Pause and engage in meaningful conversations with delivery experts during dedicated breaks 📢 Roundtable Discussions: Share insights in intimate, focussed discussions to advance extra hepatic delivery 📢 Interactive Workshops: Unlock non-viral delivery methods for RNA-based gene editing payloads during hands-on, interactive sessions See the full agenda here: https://ter.li/8ncgut Hear technical insights into the development of novel LNPs with innovative formulations and protein-conjugation as well as alternative carriers such as exosomes, polymers, peptides and more to enable safe and cell-specific delivery. Find out more here: https://ter.li/8ncgut

The wait is over—CPHIMilan2024 is here 🔮 The future of the industry is being shaped here, where revolutionary innovations, inspiring speakers, and game-changing sessions collide to set new benchmarks in the pharmaceutical world. 🌍💡 We’ve brought you the exclusive inside scoop on must-attend sessions, featuring some of the biggest names in the industry 🎤: Giulia Del Brenna, Terry Katz, Aurelio Arias, Reiner Christensen, Sudarshan Jain. Here are some sessions that are shaping the future of pharma: 🌱 Sustainability Takes the Spotlight: Decarbonisation in Drug Delivery 🤖 Manufacturing 5.0: AI, Automation, and Pharma Production 🧬 Next Gen Bio: Gene Therapies and mRNA Vaccines …and we’re just getting started! Swipe through to explore the full lineup of sessions that will shape the future of pharma and ensure you’re part of the action at #CPHIMilan2024. 🚀 This is your moment. Be there, connect with leaders, and stay ahead of the curve in pharma innovation! Informa Markets #CPHIMilan2024 #PharmaInnovation #MustAttendSessions #IndustryLeaders #FutureOfPharma #NextGenBiotech #SustainabilityInPharma

#News: MilliporeSigma reports that it has invested more than €300 million ($324.5 million) into a new bioprocessing production center in Daejeon, South Korea. The new site is the largest investment by the company’s #lifescience business sector in Asia-Pacific, according to a company spokesperson, who adds that the investment is expected to create approximately 300 additional jobs by the end of 2028. MilliporeSigma is the U.S. and Canada life science business of Merck KGaA, Darmstadt, Germany. “The Asia-Pacific region is home to a large number of institutions that conduct leading-edge and innovative research, manufacturing and services in areas such as biotechnology, mRNA, and gene therapy,” said Matthias Heinzel , member of the executive board and CEO life science, Merck KGaA. “Expanding our presence in the region will bring us even closer to our customers in this evolving and dynamic market. Our goal is to foster deep collaboration to increase the speed in bringing new therapies to patients.” Read more from Genetic Engineering & Biotechnology News 👇🏽 https://lnkd.in/ebFaD8pM

🌟 BIG NEWS ! 🌟 We are delighted to announce that Axom is a finalist in two categories at the prestigious CPHI Pharma Awards: Manufacturing Excellence and Start-up Initiative. 🎉 Being selected as one of the best innovations in two different categories is testament to the power of our solution when it comes to positively transforming the pharmaceutical industry. 🚀 Our technology is up to the challenges of the sector, which is why we believe the revolution we're bringing deserves to win. We're incredibly proud of how far we've come and the impact we've already made. Right from the start, our ai-based automated visual inspection station, designed to detect defects in pharmaceutical products, proved its worth. But why was our innovation selected? 🤔 Because it's not just one breakthrough, but incorporates at least 5 distinct technological innovations! 💡 We are also honoured to share this recognition with equally innovative fellows. We look forward to welcoming many of you to our stand 6SU95, along with those of our fellow finalists. Together, we have the power to revolutionize the pharmaceutical industry! 💊🌍 𝗠𝗮𝗻𝘂𝗳𝗮𝗰𝘁𝘂𝗿𝗶𝗻𝗴 𝗲𝘅𝗰𝗲𝗹𝗹𝗲𝗻𝗰𝗲 𝗳𝗶𝗻𝗮𝗹𝗶𝘀𝘁𝘀 : Axom – Automated Visual Inspection Systems FABRX – Revolutionising Care for Children Teva Active Pharmaceutical Ingredients – Advanced AI Optimization for API Production COMSER – LyoFlow RheaVita BV – RheaLyo™️ GMP-Flex continuous freeze-dryer BD – BD iDFill Catalent Pharma Solutions Cell & Gene Therapy – UpTempo℠ CAR-T Cell Therapy Platform Process 𝗦𝘁𝗮𝗿𝘁-𝘂𝗽 𝗜𝗻𝗶𝗮𝘁𝗶𝗮𝘁𝗶𝘃𝗲 𝗳𝗶𝗻𝗮𝗹𝗶𝘀𝘁𝘀 : Axom – Automated Visual Inspection Systems Cocoon Bioscience – Solutions for Complex Recombinant Proteins myotwin – Heart muscle contraction monitoring technology Nebu~Flow – Nebuliser Platform Oryl Photonics – ORYL Screener Galvita AG – Galvita TIP - A new standard of oral drug delivery #Innovation #Pharma #CPHIAwards #ManufacturingExcellence #Startup #Technology #RevolutionPharma #Finalist #Transformation

2023 a year of challenge for many in the market; with less deals happening across Pharma, Biotech, Medtech and services coupled with economical hurdles for early and clinical stage organisations looking to raise. Despite this, the average deal value of Pharma almost tripled and Biotech nearly doubled comparative to 2022. Perhaps with a number of phIII trials failing and pipelines looking less secure than usual has led to such an increase? Less but more. Nice! #biotech #pharma #mergersandacquisitions

Korea’s CMO companies, like Samsung Biologics and SK Bioscience, are rapidly expanding in the global market. With large-scale production and strategic partnerships, they are becoming key players in the biopharmaceutical industry. Korean CMOs are transitioning to CDMO models, offering end-to-end services from development to production. They are also adopting advanced technologies such as Cell and Gene Therapy (CGT) and RNA-based treatments to stay competitive. Expanding into emerging markets like China and Southeast Asia presents further opportunities. Meanwhile, companies are focusing on ESG management, implementing sustainable production practices to meet global standards. Key challenges include R&D investment, talent development, and enhancing global partnerships. As these companies continue to innovate and grow, their role in the global biopharma landscape is expected to strengthen significantly in the next 5–10 years.